Abstract: Aqueous emulsion of an organic polymeric material (preferably olefinic), said polymeric material comprising: 1) a hydrophobic polymer part which has a polymodal particle size distribution, and 2) an oligomer part bearing acid groups which imparts or is capable of imparting reversibility to the polymeric material of the emulsion, this being realized, if necessary, by sufficient of the acid groups being in ionised form. lonisation is usually achieved by raising pH to ≧7 (neutralizing). The polymer emulsion is particularly useful for inks and overprint lacquer formulations, and for paint formulations.

Abstract: The invention relates to quinazoline derivatives of the formula: and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

Abstract: A compound of the Formula (1) and salts thereof: wherein: Ar, Ar1, J, J1, X, X1 W, W1, L and m are as defined in the description. The compounds of Formula (1) are useful as additives in inks, especially ink jet printing inks, for reducing color bleed between adjacent printed regions. Also claimed are inks containing a compound of the Formula (1), a method of ink jet printing using the inks, a substrate printed with the ink and an ink jet printer cartridge containing the ink.

Abstract: Compounds of formula (I), wherein: n is 1 to 6; Het is a nitrogen containing ring fused to the benzene ring on two adjacent carbon atoms to form a bicyclic ring system which ring system may be optionally substituted; R1 is hydrogen, C1-8alkyl, C2-6alkenyl, C2-6alkyny, C3-8cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC1-6alkyl, heteroarylC1-6alkyl, heterocyclylC1-6alkyl or C3-8cycloalkylC1-6alkyl; R2 is C1-6alkyl, C2-6alkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occurring amino acid; R3 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocycylC1-6alkyl; R4 is hydrogen or C1-6alkyl; or R3 and R4 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R1-R4, is optionally substituted; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof, are described as inhibitors of the production of Tumor Necrosis Factor and/or one or more matr

Abstract: Herbicidal compositions containing tetrazolinone compounds and antidotal compounds therefor to reduce injury to various crops, particularly corn, wheat, rice and soya, from the phytotoxic effects of tetrazolinone herbicides when used alone or in combination with additional pesticidally active ingredients. Methods for reducing phytotoxicity or injury to crop plants, particularly corn and soya crops, due to tetrazolinone herbicides are also described.

Abstract: The invention concerns a novel chemical process for the manufacture of methyl (2S)-2-[3R)-3-(N-[tert-butyloxycarbonyl]amino)-2-oxopyrrolidin-1-yl]propionate.

Abstract: Processes for preparing compounds of the formula (I) are described: P1OOC—CH(OH)—CHR1—CONH—Z wherein P1 is hydrogen or a protecting group, Z is a group —CHR2COOP2 or —CHR2CONR3R4 wherein P2 is hydrogen or a protecting group and R1-R4 are values known in the TNF-inhibitor art. The compounds of the formula (I) are useful in inhibiting TNF and one or more matrix metalloproteinase enzymes. One intermediate in a process of the invention is formula (II).

Abstract: A method for enhancing the expression of a tomato phytoene synthese gene in a plant while avoiding or reducing co-suppression involves the synthesis of a DNA which is altered in nucleotide sequence (SEQ ID NO:1) and is capable of expression of a protein, ideally identical to that of a protein already expressed by a DNA already present in the plant. This method ensures that sequence similarity between the two genes is reduced enough to eliminate the phenomenon of co-suppression, allowing the over-expression of a specific phytoene synthese protein.

Abstract: 1. An ink comprising water, a water-dissipatable polymer and a dye, wherein the dye carries a group of the Formula (1): wherein: R1 is optionally substituted branched chain alkyl; and R2 is H, optionally substituted alkyl or optionally substituted aryl. The inks are useful in ink jet printers.

Abstract: A method of characterizing a test sample of genomic DNA which method comprises contacting the test sample with type specific primer to prime selectively, within a telomere repeat array, internal repeat units of that type, and extending the type specific primers in the presence of appropriate nucleoside triphosphates and an agent for polymerization thereof to produce a set of amplification products extending from the internal repeat units of that type to at least the end of the telomere repeat array.

Abstract: Cyclic peptide of formula (1) where Xaa1 is selected from L-amino acids selected from Phe, Lys and Arg, D-amino acids selected from Phe and Met, the L- and D-amino acid optionally substituted on its &agr;-carbon or its &agr;-amino group with a C1-4 alkyl group; and Melle; Xaa2, Xaa3 et Xaa4 are respectively Leu, Asp and Val, optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; X1 is selected from D-amino acids selected from Ala, Phe, Arg, Lys, Trp, hArg(Et)2, Orn(CHMe2), Orn(Me2), Lys(CHMe2) and Arg(Pmc), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; Formula (II); NH(CH2)5CO; and NH(CH2)2S(CH2)yCO, where y is 1 or 2; X2 is selected from D-amino acids selected from Ala, Arg, Lys, His, hArg(Et)2, Orm(CHMe2), and Om(Me2), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; NH(CH2)SCH2CO; and NH(CH2)xCO, where x is 2 or 3; Xaa5 and Xaa6 are each independently a

Abstract: Compounds of formula I wherein Q1, Q2, Q3, Q4 and Q5 have any of the meanings given in the specification, their N-oxides, and their pharmacuetically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.

Abstract: The present invention relates to compounds, pharmaceutical compositions and methods of using compounds having the formula below in the treatment and prevention of certain diseases or conditions. Where the ring designated A is chosen from ortho substituted aryl or heteroaryl species, R1 and R2 are chosen independently from —(CH2)nL where L is selected from a variety of substituents including hydrogen, and aryl, heteroaryl or heterocyclic groups and R4 is chosen from a variety of substituents including halogen and alkyl groups. The compounds are useful in treating and preventing neurological disorders associated with excitatory amino acids.

Abstract: An ink composition comprising: (a) from 0.1 to 50 parts of a dye; (b) from 0.1 to 50 parts of a sugar; (c) from 0.1 to 50 parts of a compound selected from phosphoric acid and a carboxylic acid or a salt thereof; (d) from 0 to 10 parts of a pH buffer; and (e) from 10 to 99 parts of a liquid medium; wherein all parts are by weight and the total number of parts (a)+(b)+(c)+(d)+(e)=100. Also claimed is a recording sheet comprising a substrate coated or impregnated with a sugar, a compound selected from phosphoric acid and a carboxylic acid or a salt thereof and optionally a binder; a coating composition; a method of ink jet printing; a substrate printed according to the method; and an ink jet printer cartridge which contains the ink and/or the coating composition.

Abstract: There are described processes for the preparation of a compound of formula I and novel intermediates in the preparative process.

Abstract: The present invention provides a phenanthroline derivative of formula (I) 1

Abstract: A promoter comprising the DNA sequence of an oil seed rape cysteine protease gene promoter of class 1, 2 or 6 is described. The promoter may be used in an expression system for at least the tissue or tissues of a germinating seedling or developing grain or plant (e.g. in the root, cotyledons, leaves and stem). In a preferred embodiment, the expression system comprises a disrupter gene fused to a promoter according to the present invention.

Abstract: The formation of undesirable sludge in the course of spraying a solution or dispersion of a water-soluble or water-dispersible solid or a structured gel formulation is reduced by the incorporation in the formulation of a low-density solid particulate material having a density of less than one and a diameter of less than the spray nozzle filter through which it will pass. The low-density solid particulate material is preferably a hollow glass or plastic particle having a density of less than 0.8 g/cm3. The invention is particularly applicable to agrochemical formulations.